Abstract
Pericardial effusion leading to cardiac tamponade can occur due to a
multitude of etiologies, one of which is medication adverse effects. In
patients with comorbid conditions, this can prove to be a challenge in
its co-management along with the primary disease. We present a rare case
of anagrelide-induced pericardial effusion that is presented with
tamponade physiology in a patient with essential thrombocythemia. After
cautiously weighing the risks and benefits of further invasive
interventions following an unsuccessful pericardiocentesis, the decision
was to stop anagrelide while managing the pericardial effusion
medically. Therefore, managing pericardial effusion should be tailored
to each patient individually through shared-decision making.